SCHEMBL4672188

SCHEMBL4672188

O=C(C=C(O)c1nc[nH]n1)c1occc1Cc1ccccn1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 2/20 0.34
HCRTR1 O43613 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
PTPRA P18433 1/20 0.32
ALOX5 P09917 1/20 0.32
ALOX5AP P20292 1/20 0.32
LMNA P02545 2/20 0.32
KDM4E B2RXH2 2/20 0.32
RAB9A P51151 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NPC1 O15118 1/20 0.32
TSHR P16473 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
PKM P14618 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677199 0.87 HRH1 (0.33) ALDH1A1SMN1; SMN2KDM4EKMT2A
SCHEMBL4673098 0.84 L3MBTL1 (0.39) ALDH1A1L3MBTL1MAPTHTTSMN1; SMN2
SCHEMBL4676488 0.84 CES1 (0.34) ALDH1A1L3MBTL1MAPTHTTHCRTR1
SCHEMBL4674356 0.84 LMNA (0.32) ALDH1A1LMNARAB9ANPC1
SCHEMBL4671783 0.83 NLRP3 (0.35) ALDH1A1SMN1; SMN2ALOX5ALOX5APLMNA
SCHEMBL4675423 0.83 HRH1 (0.33) L3MBTL1MAPTALOX5ALOX5APLMNA
SCHEMBL4677069 0.83 KMT2A (0.33) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL4673125 0.82 KDM4E (0.36) ALDH1A1MAPTHTTSMN1; SMN2PTPRA
SCHEMBL4672457 0.82 TSHR (0.33) ALDH1A1MAPTHTTSMN1; SMN2PTPRA
SCHEMBL4677341 0.82 CYP2C9 (0.39) ALDH1A1L3MBTL1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885L3MBTL1 1170/4885MAPT 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.